Guardian Pharmacy Services, Inc.
NYSE:GRDNMedical - Distribution
+$0.17 today
- Market cap
- $3.09B
- Beta
- 0.08
- P/E (TTM)
- 52.0
- EPS (TTM)
- $0.84
Volume 0.45M
Average 0.48M
GRDN Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Guardian Pharmacy Services, Inc.NYSE: GRDN
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow declines year over year
Q2 FY2026 financing cash flow of $726K (cash outflow) fell 65.7% year over year, behind the -36.8% change in trailing-twelve-month financing cash flow. Sequentially, it fell 65.7% from the prior quarter. Over 3 fiscal years it compounded at -46.0% a year.
Context
- Financing cash flow amounted to 0.5% of revenue in FY2025, down 1.4 pp from a year earlier.
- Financing cash flow grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -65.7% toward the trailing-twelve-month pace of -36.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (7.07M) USD
- Year-over-year change
- +70.1%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (7.07M) | +70.1% |
| FY2024 | 2024-12-31 | (23.65M) | +58.7% |
| FY2023 | 2023-12-31 | (57.23M) | -27.1% |
| FY2022 | 2022-12-31 | (45.03M) | -22.4% |
| FY2021 | 2021-12-31 | (36.79M) | — |
Financing Cash Flow vs competitors
How GRDN compares with its peers on the latest reported figures
- GRDN's LTM Jun 2026 financing cash flow of $5.13M is the 10th largest of the 11 companies compared; the peer median is $22.16M.
- Its year-over-year change of -36.8% is the 6th highest of 11, against a peer median of -44.5%.
- Financing cash flow amounts to 0.4% of revenue for GRDN, versus a peer median of 12.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $446.68M | +1465.1% | +688.5% | 97.2% | |
| LTM Sep 2026 | $384.41M | +443.1% | +41.8% | 24.3% | |
| LTM Sep 2026 | $234.94M | +436.2% | -39.6% | 12.0% | |
| LTM Jun 2026 | $179.14M | -6.5% | +434.4% | 105.4% | |
| LTM Mar 2026 | $175.8M | +107.1% | -14.8% | 6.6% | |
| LTM Sep 2026 | $34.21M | -82.5% | +14.8% | — | |
| LTM Jun 2026 | $15.33M | -110.4% | — | 12.7% | |
| LTM Mar 2026 | $10.12M | -94.3% | +45.8% | 3.1% | |
| LTM Mar 2026 | $7.94M | -98.0% | +114.7% | 36.7% | |
GRDNGuardian Pharmacy Services, Inc. | LTM Jun 2026 | $5.13M | -36.8% | -46.0% | 0.4% |
| LTM Jun 2026 | $2.54M | -129.5% | -24.5% | 0.4% | |
| Peer median (excluding GRDN) | $22.16M | -44.5% | +41.8% | 12.7% | |
Competitors are the stored peer set for GRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 28.33M | 49.66M | 37.72M | (71.03M) | 49.22M |
| Depreciation & Amortization | 16.53M | 16.56M | 18.23M | 19.77M | 22.34M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 3.07M |
| Stock-Based Compensation | 13.03M | (3.38M) | (6.09M) | 131.49M | 13.85M |
| Change in Working Capital | (1.47M) | (18.72M) | 15.6M | (29.41M) | 6.38M |
| Accounts Receivables | (7.71M) | (16.79M) | (14.3M) | (25.49M) | (8.55M) |
| Inventory | (240K) | (8.12M) | 4.43M | (1.15M) | (877K) |
| Accounts Payables | 9.78M | 13.37M | 6.3M | 13.23M | 16.4M |
| Other Working Capital | (3.3M) | (7.17M) | 19.18M | (16M) | (586K) |
| Other Non-Cash Items | 2.08M | 4.4M | 5.35M | 7.14M | 5.43M |
| Operating Cash Flow | 58.5M | 48.52M | 70.82M | 57.96M | 100.29M |
| Capital Expenditures | (9.28M) | (16.77M) | (14.56M) | (16.37M) | (19.58M) |
| Acquisitions (Net) | (4.4M) | (2M) | (985K) | (14.71M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 535K | 874K | 2.1M | 671K | (12.68M) |
| Investing Cash Flow | (13.15M) | (17.9M) | (13.44M) | (30.41M) | (32.26M) |
| Debt Repayment | (6.1M) | (2.8M) | (2.89M) | (36.48M) | (4.98M) |
| Common Stock Issued | 0 | 0 | 0 | 119.78M | 27.45M |
| Common Stock Repurchased | 0 | 0 | 0 | (55.18M) | (29.04M) |
| Dividends Paid | (17.36M) | (30.8M) | (38.42M) | (35.75M) | 0 |
| Other Financing Activities | (13.34M) | (11.42M) | (15.92M) | (16.02M) | (497K) |
| Financing Cash Flow | (36.79M) | (45.03M) | (57.23M) | (23.65M) | (7.07M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 8.56M | (14.41M) | 145K | 3.91M | 60.96M |
| Free Cash Flow | 49.22M | 31.75M | 56.26M | 41.59M | 80.71M |
Guardian Pharmacy Services, Inc.
NYSE:GRDN
Intrinsic Alpha fair value
Locked
Current Price
$48.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.